WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker and AdvaMedDx® Executive Director Susan Van Meter issued the following statements upon congressional passage of the Laboratory Access for Beneficiaries (LAB) Act as part of the…
Contact: Mark [email protected] WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker today released the following statement on Senate passage of full repeal of the medical device excise tax: “On behalf…
WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) issued the following statement from President and CEO Scott Whitaker on the U.S. House of Representatives’ vote to repeal the medical device…
WASHINGTON, D.C. – AdvaMed® President and CEO Scott Whitaker released the following statement on the announcement by congressional leadership of a funding agreement that includes full repeal of the medical…
WASHINGTON, D.C. – In an op-ed published today in Morning Consult, AdvaMed® President and CEO Scott Whitaker urges Congress to act before the medical device excise tax comes back into effect Jan. 1.
WASHINGTON, D.C. – The Advanced Medical Technology Association® (AdvaMed®) issued the following statement today from President and CEO Scott Whitaker regarding the U.S. Senate’s confirmation of Dr. Stephen Hahn to…
WASHINGTON, D.C. – In today’s Wall Street Journal, the editorial board wrote that Congress “should stop a return of the destructive” medical device excise tax scheduled to go into effect on Jan.…
WASHINGTON, D.C. – More than half of medical device company employees expect reinstatement of the medical device excise tax in 2020 to lead both to job losses and cuts to research…
Washington, D.C. – The Advanced Medical Technology Association® (AdvaMed®) today issued the following statement from President and CEO Scott Whitaker on the newly upgraded United States-Mexico-Canada Agreement (USMCA):
WASHINGTON, D.C. – The Medical Alley Association yesterday released a survey of its membership demonstrating that if the medical device tax is reinstated on Jan. 1, 2020, 83 percent of medtech companies…